| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5709ae4638c4b4e735d0aa58377cb6c7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-485 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2016-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f4c66a78c22b06baaff0eb620c0514a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82f3765aba14eea822edc40183371840
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_689a18d86b3c1511b47eb0fb747e9307
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5594fd2e4c3c1bd0873a4baaf68b2728
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d89664f57622ed06d67380e629e46cce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee98906bf4bb849931ac17bfd72e9711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b27fa217437527520095df4c4106786
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea0bf383b967d2b2776ceae7e3baeded
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_022866a37fd24aa7b18574f31d7b12f0 |
| publicationDate |
2017-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2626682-C1 |
| titleOfInvention |
Method for predicting tumour resistance to tethegeth therapy of cetuximab in patients with plane-cellular language of language and multidisal bottom of the pta |
| abstract |
FIELD: medicine. n SUBSTANCE: invention is a method for predicting tumour resistance to target therapy of cetuximab in patients with squamous cell carcinoma of the tongue and oral mucosa including a blood test, characterized in that two days before the initiation of a chemo-chemotherapy treatment with the inclusion of targeted cetuximab therapy in a patient with squamous cell carcinoma of the tongue And the mucosal bottom is determined by EGF, sEGFR, then the ratio of EGF/sEGFR is calculated and at a value of this ratio between 55.3-66.9 it is predicted that there is no resistance against Plaques to cetuximab therapy, and with the value of this indicator within 92.6-117.8 predict the presence of tumour resistance to cetuximab therapy. n EFFECT: early prognosis of tumour resistance to targeted therapy with cetuximab. n 2 ex, 1 tbl |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2802446-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2713453-C1 |
| priorityDate |
2016-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |